| Name | Title | Contact Details |
|---|---|---|
Patricia Christiansen |
Sr. Director of Consumer Marketing Technology Infrastructure | Profile |
Boundless Bio, a San Diego based company backed by ARCH Venture Partners, is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.
i-FACTOR Peptide Enhanced Bone Graft is a drug/device combination that creates a new category of bone graft technology. Take a moment to review our introduction to i-FACTOR, our Level-1 IDE study and comparative performance sections given below.
Our patented and award-winning Highlight® technology makes it easy to use disinfectants correctly.
KalVista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
Champions Oncology is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.